Kiromic BioPharma provides updates on its Deltacel-01 clinical trial

Kiromic BioPharma reports follow-up results from the second, third and fourth patients enrolled in its Deltacel-01 Phase 1 clinical trial. This trial is evaluating Deltacel, the Company’s allogeneic, off-the-shelf, Gamma Delta T-cell therapy, in patients with stage 4 metastatic non-small cell lung cancer who have failed to respond to standard therapies. The third and fourth patients showed stable disease at their four- and two-month follow-up visits, respectively. Both patients are doing well, and neither showed any dose-limiting toxicities. Patients three and four are being treated at the Beverly Hills Cancer Center.